Recursion Updates AI Drug Platform, Financial Outlook at JPM

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
pharmaphorum

Changing Faces: Digital and supplier hires, November and December 2025

Amber Implants, a Netherlands medtech developing next-generation implants for spinal injuries, named Vincent Gardès as CEO.

2 AI stocks to buy in 2026, and 1 to avoid

And its investments in AI could, eventually, lead to important monetization opportunities even beyond advertising, perhaps ...
MarketBeat on MSN

AI Pharma: 2 Paths to AI-Powered Drug Investment

The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence ...

Anthropic launches Cowork, a Claude Desktop agent that works in your files — no coding required

Anthropic’s Cowork brings Claude Code–style AI agents to the desktop, letting Claude access and manage local files and browse ...

Assessing Whether Recursion Pharmaceuticals (RXRX) Looks Undervalued After Recent Trading Volatility

Why Recursion Pharmaceuticals Is On Investors’ Radar Recursion Pharmaceuticals (RXRX) has been drawing attention after recent ...
Barron's

Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...